GC BIOPHARMA CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113,500 KRW | -1.90% |
|
+2.16% | -9.56% |
| May. 03 | Green Cross Widens Q1 Loss, Sales Inch Up 2% | MT |
| Mar. 20 | GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 1,744B 1.29B | Sales 2025 * | 1,855B 1.37B | Capitalization | 1,295B 956M |
|---|---|---|---|---|---|
| Net income 2024 * | 29B 21.4M | Net income 2025 * | 48B 35.42M | EV / Sales 2024 * | 1.1 x |
| Net Debt 2024 * | 617B 455M | Net Debt 2025 * | 562B 415M | EV / Sales 2025 * | 1 x |
| P/E ratio 2024 * |
45.3
x | P/E ratio 2025 * |
27.3
x | Employees | 2,098 |
| Yield 2024 * |
1.51% | Yield 2025 * |
1.51% | Free-Float | 46.21% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.90% | ||
| 1 week | +2.16% | ||
| Current month | -0.70% | ||
| 1 month | -8.02% | ||
| 3 months | +1.25% | ||
| 6 months | +14.65% | ||
| Current year | -9.56% |
1 week
112 000.00
116 500.00
1 month
108 600.00120 200.00
Current year
107 600.00127 800.00
1 year
93 000.00134 300.00
3 years
93 000.00398 000.00
5 years
93 000.00538 000.00
10 years
93 000.00538 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eun-Cheol Huh
CEO | Chief Executive Officer | 52 | 05-12-31 |
Ok-Gyu Go
CMP | Compliance Officer | - | 13-12-31 |
In-Jae Lee
BRD | Director/Board Member | 61 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Il-Sup Huh
PRN | Corporate Officer/Principal | 70 | - |
Eun-Cheol Huh
CEO | Chief Executive Officer | 52 | 05-12-31 |
Byeong-Hwa Kim
BRD | Director/Board Member | 65 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.38% | 2 M€ | -14.14% | ||
| 0.05% | 2 M€ | -.--% | ||
| 0.01% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 113,500 | -1.90% | 29,829 |
| 24-05-02 | 115,700 | +1.22% | 15,472 |
| 24-04-30 | 114,300 | -0.70% | 13,946 |
| 24-04-29 | 115,100 | +2.86% | 14,634 |
| 24-04-26 | 111,900 | +0.72% | 5,743 |
End-of-day quote Korea S.E., May 02, 2024
More quotes
Green Cross Corp is a Korea-based company that mainly engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures pharmaceutical products including blood products, general products, vaccines, over the counter (OTC) drugs, diagnostic reagents, placental injections, cell therapies, vaccine fertilized eggs and blood diagnostic products, among others. The Company also provides genome analysis services.
Sector
Pharmaceuticals
Calendar
2024-11-13
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
113,500
KRW
Average target price
144,667
KRW
Spread / Average Target
+27.46%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.56% | 964M | |
| +26.08% | 681B | |
| +21.85% | 556B | |
| -4.77% | 361B | |
| +16.97% | 325B | |
| +5.69% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B |
- Stock Market
- Equities
- A006280 Stock
